Evidence map›Paper›PMID 39205204›Full record

ArticleViruses2024

Phylogenetic Network Analyses Reveal the Influence of Transmission Clustering on the Spread of HIV Drug Resistance in Quebec from 2002 to 2022.

Bluma G Brenner, Ruxandra-Ilinca Ibanescu, Maureen Oliveira, Guillaume Margaillan, Bertrand Lebouché, Réjean Thomas, Jean Guy Baril, René-Pierre Lorgeoux, Michel Roger, Jean-Pierre Routy and 1 more

Abstract read
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bluma G BrennerMcGill University Centre for Viral Diseases, Lady Davis Institute for Medical Research, Montreal, QC H3T 1E2, Canada.ORCID 0000-0002-2084-728X
Ruxandra-Ilinca IbanescuMcGill University Centre for Viral Diseases, Lady Davis Institute for Medical Research, Montreal, QC H3T 1E2, Canada.
Maureen OliveiraMcGill University Centre for Viral Diseases, Lady Davis Institute for Medical Research, Montreal, QC H3T 1E2, Canada.
Guillaume MargaillanDépartement de Microbiologie et d'Immunologie et Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC H2X 0C1, Canada.
Bertrand LebouchéChronic Viral Illness Service, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.ORCID 0000-0002-1273-9393
Réjean ThomasClinique Médicale l'Actuel, Montreal, QC H2L 4P9, Canada.
Jean Guy BarilClinique Médicale du Quartier Latin, Montreal, QC H2L 4E9, Canada.
René-Pierre LorgeouxGilead Sciences Inc., Montreal, QC L5N 7K2, Canada.
Michel RogerDépartement de Microbiologie et d'Immunologie et Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC H2X 0C1, Canada.
Jean-Pierre RoutyChronic Viral Illness Service, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.ORCID 0000-0001-9897-7589
The Montreal Primary Hiv Infection Phi Cohort Study GroupPrimary HIV Infection (PHI) Cohort, Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.

Funding

FRQS-Reseau SIDA 339583Gilead Sciences 15291,23131
6 · The paper itself

Abstract

backgroundHIV drug resistance (HIV-DR) may jeopardize the benefit of antiretroviral therapy (ART) in treatment and prevention. This study utilized viral phylogenetics to resolve the influence of transmission networks on sustaining the spread of HIV-DR in Quebec spanning 2002 to 2022.

methodsTime trends in acquired (ADR) and transmitted drug resistance (TDR) were delineated in treatment-experienced (

resultsDespite steady declines in treatment failure and ADR since 2007, rates of TDR among newly infected, ART-naive persons remained at 14% spanning the 2007-2011, 2012-2016, and 2017-2022 periods. Notably, half of new infections among men having sex with men and heterosexual groups were linked in large, clustered networks having a median of 35 (14-73 IQR) and 16 (9-26 IQR) members per cluster, respectively. Cluster membership and size were implicated in forward transmission of non-nucleoside reverse transcriptase inhibitor NNRTI RAMs (9%) and thymidine analogue mutations (TAMs) (5%). In contrast, transmission of M184V, K65R, and integrase inhibitors (1-2%) remained rare. Levels of TDR reflected viral replicative fitness. The median baseline viremia in ART-naïve groups having no RAMs, NNRTI RAMs, TAMs, and M184VI were 46.088, 38,447, 20,330, and 6811 copies/mL, respectively (

conclusionPhylogenetics emphasize the need to prioritize ART and pre-exposure prophylaxis strategies to avert the expansion of transmission cascades of HIV-DR.

Indexed as

Anti-HIV AgentsDrug Resistance, ViralHIV-1HIV InfectionsPhylogenyAdultCluster AnalysisFemaleHumansMaleMiddle AgedMutationQuebecAnti-HIV Agentsacquired and transmitted drug resistanceantiretroviral therapyHIV-1M184Vphylogenetic clustering

Identifiers

PMID39205204
PMCPMC11359670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.